DUBLIN--(BUSINESS WIRE)--Nov 8, 2019--

The "Topoisomerase Inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Topoisomerase Inhibitor - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Topoisomerase Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Topoisomerase Inhibitor

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Topoisomerase Inhibitor

The report assesses the active Topoisomerase Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

  • Provides a snapshot of the therapeutics pipeline activity for Topoisomerase Inhibitor
  • Features the Topoisomerase Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Topoisomerase Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Topoisomerase Inhibitor

Reasons to Buy

  • Establish a comprehensive understanding of the current pipeline scenario across Topoisomerase Inhibitor to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Topoisomerase Inhibitor research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Topoisomerase Inhibitor
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Topoisomerase Inhibitor to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress

Companies Mentioned

  • GSK
  • Intezyme
  • RedxPharma

Key Topics Covered

1. Report Introduction

2. Topoisomerase Inhibitor - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Topoisomerase Inhibitor

4. Comparative Analysis

5. Topoisomerase Inhibitor Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Topoisomerase Inhibitor Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tct40s

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/08/2019 05:08 AM/DISC: 11/08/2019 05:08 AM

Copyright Business Wire 2019.